Confounding Factors of the Diabetes - Metformin - Cancer Relationship

Open access


An increasing wealth of knowledge in oncology and diabetes points to metformin, the most widely used oral anti-diabetic worldwide, as a potential anticancer drug. Metformin has not only been shown to reduce the risk of developing cancer, but recent studies have also highlighted the impact that this drug might have on cancer aggressiveness, progression and survival. Several categories of confounding factors, some of them not taken into account in current clinical studies, may lead to an incorrect estimation of the true effect that metformin might have in cancer patients. It is important to assess whether the insulin lowering effects of metformin may constitute the main antineoplastic mechanism of action or if this may be due to an underlying direct effect. Such reasons warrant that new prospective research should take into account patient insulin levels, the duration and doses of metformin treatment and also include a cohort of non-diabetic patients for comparison. Measurement of the optimal antineoplastic dosage of metformin and proper quantification of established confounding factors will likely lead to a better understanding and estimation of metformin’s true anti-cancer effects, ultimately resulting in a better clinical management for diabetic patients with cancer.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Jiralerspong S Palla SL Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302 2009.

  • 2. Thakkar B Aronis KN Vamvini MT Shields K Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62: 922-934 2013.

  • 3. Glueck CJ Fontaine RN Wang P et al. Metformin reduces weight centripetal obesity insulin leptin and low-density lipoprotein cholesterol in nondiabetic morbidly obese subjects with body mass index greater than 30. Metabolism 50: 856-861 2001.

  • 4. Hirsch HA Iliopoulos D Tsichlis PN Struhl K. Metformin selectively targets cancer stem cells and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511 2009.

  • 5. Pawelczyk L Spaczynski RZ Banaszewska B Duleba AJ. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 113: 209-213 2004.

  • 6. Calle EE Kaaks R. Overweight obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591 2004.

  • 7. Jalving M Gietema JA Lefrandt JD et al. Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380 2010.

  • 8. Malki A Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res 19: 275-285 2011.

  • 9. Deng XS Wang S Deng A et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11: 367-376 2012.

  • 10. Zheng L Yang W Wu F et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res 19: 5372-5380 2013.

  • 11. Protani M Coory M Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123: 627-635 2010.

  • 12. Batty GD Shipley MJ Jarrett RJ Breeze E Marmot MG Smith GD. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int J Obes (Lond) 29: 1267-1274 2005.

  • 13. Calle EE Rodriguez C Walker-Thurmond K Thun MJ. Overweight obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638 2003.

  • 14. Rodriguez C Patel AV Calle EE Jacobs EJ Chao A Thun MJ. Body mass index height and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10: 345-353 2001.

  • 15. Lo J Bernstein LE Canavan B et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 293: E102-109 2007.

  • 16. Heilbronn LK Campbell LV. Adipose tissue macrophages low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 14: 12251230 2008.

  • 17. Brandebourg T Hugo E Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 9: 464-476 2007.

  • 18. Rink M Xylinas E Babjuk M et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 188: 2120-2127 2012.

  • 19. Rink M Furberg H Zabor EC et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 63: 724-732 2013.

  • 20. McMahon PM Kong CY Johnson BE et al. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal 32 Suppl 1: S117-124 2012.

  • 21. Xu M Chen G Fu W et al. Ethanol disrupts vascular endothelial barrier: implication in cancer metastasis. Toxicol Sci 127: 42-53 2012.

  • 22. Husein-Elahmed H Aneiros-Fernandez J Gutierrez-Salmeron MT Botella-Lopez M Aneiros-Cachaza J Naranjo-Sintes R. Alcohol intake and risk of aggressive histological basal cell carcinoma: a case-control study. Eur J Dermatol 22: 525-530 2012.

  • 23. Meyerhardt JA Heseltine D Niedzwiecki D et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 24: 3535-3541 2006.

  • 24. Irwin ML Smith AW McTiernan A et al. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health eating activity and lifestyle study. J Clin Oncol 26: 3958-3964 2008.

  • 25. Holmes MD Chen WY Feskanich D Kroenke CH Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA 293: 2479-2486 2005.

  • 26. Scott E Daley AJ Doll H et al. Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control 24: 181-191 2013.

  • 27. Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol 30: 3697-3704 2012.

  • 28. Ellsworth RE Valente AL Shriver CD Bittman B Ellsworth DL. Impact of lifestyle factors on prognosis among breast cancer survivors in the USA. Expert Rev Pharmacoecon Outcomes Res 12: 451-464 2012.

  • 29. Currie CJ Poole CD Jenkins-Jones S Gale EA Johnson JA Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35: 299-304 2012.

  • 30. Bowker SL Yasui Y Veugelers P Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53: 1631-1637 2010.

  • 31. Kesikli SA Unluturk U Kilickap S. Insulin therapy and cancer-specific mortality in patients with colorectal cancer and diabetes. J Clin Oncol 30: 17291730; author reply 1730-1722 2012.

  • 32. Nakai Y Isayama H Sasaki T et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas 42: 202-208 2013.

  • 33. Wein S Sulkes A Stemmer S. The oncologist’s role in managing depression anxiety and demoralization with advanced cancer. Cancer J 16: 493-499 2010.

  • 34. Johansson M Ryden A Finizia C. Mental adjustment to cancer and its relation to anxiety depression HRQL and survival in patients with laryngeal cancer - a longitudinal study. BMC Cancer 11: 283 2011.

  • 35. Hamer M Chida Y Molloy GJ. Psychological distress and cancer mortality. J Psychosom Res 66: 255258 2009.

  • 36. Savas S Hyde A Stuckless SN Parfrey P Younghusband HB Green R. Serotonin transporter gene (SLC6A4) variations are associated with poor survival in colorectal cancer patients. PLoS One 7: e38953 2012.

  • 37. Han L Ma Q Li J et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One 6: e27074 2011.

  • 38. Pan J Chen C Jin Y et al. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle 11: 2314-2326 2012.

  • 39. Gallagher EJ LeRoith D. Diabetes cancer and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 1243: 54-68 2011.

  • 40. Giovannucci E Harlan DM Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685 2010.

  • 41. Goodwin PJ Ennis M Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20: 4251 2002.

  • 42. Pollak M Chapman J Shepherd L et al. Insulin resistance estimated by serum C-peptide level is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA. 14 adjuvant breast cancer trial. J Clin Oncol 24 no. 18S: 524 2006.

  • 43. Irwin ML Duggan C Wang CY et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health eating activity and lifestyle study. J Clin Oncol 29: 47-53 2011.

  • 44. Onitilo AA Engel JM Glurich I Stankowski RV Williams GM Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23: 991-1008 2012.

  • 45. Duggan C Irwin ML Xiao L et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29: 32-39 2011.

  • 46. Chen TM Lin CC Huang PT Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 26: 858865 2011.

  • 47. Landman GW Kleefstra N van Hateren KJ Groenier KH Gans RO Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326 2010.

  • 48. Yancik R Wesley MN Ries LA Havlik RJ Edwards BK Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285: 885-892 2001.

  • 49. Wong ND Glovaci D Wong K et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res 9: 146-152 2012.

  • 50. Schwartz AV Vittinghoff E Sellmeyer DE et al. Diabetes-related complications glycemic control and falls in older adults. Diabetes Care 31: 391-396 2008.

  • 51. Richardson LC Pollack LA. Therapy insight: Influence of type 2 diabetes on the development treatment and outcomes of cancer. Nat Clin Pract Oncol 2: 48-53 2005.

  • 52. Lee JH Kim TI Jeon SM Hong SP Cheon JH Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 131: 752-759 2012.

  • 53. Romero IL McCormick A McEwen KA et al. Relationship of type II diabetes and metformin use to ovarian cancer progression survival and chemosensitivity. Obstet Gynecol 119: 61-67 2012.

Journal information
Impact Factor

CiteScore 2018: 0.19

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.229

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 751 368 13
PDF Downloads 371 236 33